Source: Eur Respir J 2012; 40: 9-11
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Loddenkemper Robert, Sotgiu Giovanni, Mitnick Carole D.. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?. Eur Respir J 2012; 40: 9-11

Member's Comments

No comment yet.

Related content which might interest you: Multidrug resistant tuberculosis: clinical aspects and management Source: Eur Respir J 2001; 18: Suppl. 33, 235s Year: 2001 Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Multidrug resistant pulmonary TB: Characteristics of drug resistance profiles of MBT in Ukraine Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required? Source: Eur Respir J 2013; 42: 1148-1150 Year: 2013 Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis Source: Eur Respir J 2012; 39: 1511-1519 Year: 2012 Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013 Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia Source: Eur Respir J 2012; 40: 133-142 Year: 2012 Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Aminoglycoside ototoxicity monitoring in multidrug resistant tuberculosis: How much is enough? Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013 Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Source: Eur Respir J 2008; 31: 904-905 Year: 2008 MDR-TB management: what is new? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 Multidrug resistant tuberculosis in non HIV patients Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 Multidrug resistance of M. tuberculosis and its infuence on treatment efficiency of new detected patients with pulmonary tuberculosis in penitentiary institutions of Belarus Source: Eur Respir J 2007; 30: Suppl. 51, 272s Year: 2007 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015